Analysts predict that Miragen Therapeutics Inc. (NASDAQ:MGEN) will post earnings per share of ($0.29) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Miragen Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.30). Miragen Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which would suggest a positive year over year growth rate of 14.7%. The firm is scheduled to issue its next earnings results on Friday, August 10th.
On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.01). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.38) to ($1.15). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Miragen Therapeutics.
Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. The company had revenue of $4.78 million for the quarter, compared to analysts’ expectations of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%.
A number of research firms recently commented on MGEN. Zacks Investment Research cut shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 16th. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of Miragen Therapeutics in a research note on Monday, April 30th. Cowen reiterated a “hold” rating on shares of Miragen Therapeutics in a research note on Monday, April 9th. Jefferies Group started coverage on shares of Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Cann reiterated a “buy” rating and issued a $13.00 price objective on shares of Miragen Therapeutics in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. Miragen Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.11.
NASDAQ:MGEN opened at $6.97 on Friday. The company has a current ratio of 20.91, a quick ratio of 20.91 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $207.12 million, a P/E ratio of -5.05 and a beta of 1.32. Miragen Therapeutics has a 12 month low of $5.01 and a 12 month high of $15.91.
A number of institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in Miragen Therapeutics in the 1st quarter valued at approximately $409,000. CVI Holdings LLC purchased a new position in Miragen Therapeutics in the 1st quarter valued at approximately $646,000. Opaleye Management Inc. purchased a new position in Miragen Therapeutics in the 1st quarter valued at approximately $7,430,000. Citadel Advisors LLC purchased a new position in shares of Miragen Therapeutics during the 1st quarter valued at $117,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Miragen Therapeutics by 151.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 164,447 shares of the medical research company’s stock valued at $1,153,000 after purchasing an additional 99,163 shares in the last quarter. Institutional investors and hedge funds own 33.15% of the company’s stock.
About Miragen Therapeutics
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.
Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.